RT Journal Article
T1 Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
A1 Cuneo, Antonio
A1 Follows, George
A1 Rigolin, Gian Matteo
A1 Piciocchi, Alfonso
A1 Tedeschi, Alessandra
A1 Trentin, Livio
A1 Perez, Angeles Medina
A1 Coscia, Marta
A1 Laurenti, Luca
A1 Musuraca, Gerardo
A1 Farina, Lucia
A1 Delgado, Alfredo Rivas
A1 Orlandi, Ester Maria
A1 Galieni, Piero
A1 Mauro, Francesca Romana
A1 Visco, Carlo
A1 Amendola, Angela
A1 Billio, Atto
A1 Marasca, Roberto
A1 Chiarenza, Annalisa
A1 Meneghini, Vittorio
A1 Ilariucci, Fiorella
A1 Marchetti, Monia
A1 Molica, Stefano
A1 Re, Francesca
A1 Gaidano, Gianluca
A1 Gonzalez, Marcos
A1 Forconi, Francesco
A1 Ciolli, Stefania
A1 Cortelezzi, Agostino
A1 Montillo, Marco
A1 Smolej, Lukas
A1 Schuh, Anna
A1 Eyre, Toby A
A1 Kennedy, Ben
A1 Bowles, Kris M
A1 Vignetti, Marco
A1 de la Serna, Javier
A1 Moreno, Carol
A1 Foà, Robin
A1 Ghia, Paolo
A1 GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
AB We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion.
YR 2018
FD 2018-04-19
LK http://hdl.handle.net/10668/12372
UL http://hdl.handle.net/10668/12372
LA en
DS RISalud
RD Apr 5, 2025